ViroPharma to Present at the UBS Global Life Sciences Conference

Wednesday, September 19, 2007 General News
Email Print This Page Comment
Font : A-A+

EXTON, Pa., Sept. 18 ViroPharma Incorporated(Nasdaq: VPHM) today announced that Michel de Rosen, president and chiefexecutive officer of ViroPharma, will present at the UBS Global Life SciencesConference at 4:00 P.M. ET on Tuesday, September 25, 2007. The conference isbeing held at the Grand Hyatt in New York.

ViroPharma's presentation will be webcast live for investors throughwww.viropharma.com and available through October 4, 2007.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to thedevelopment and commercialization of products that address serious diseasestreated by physician specialists and in hospital settings. ViroPharmacommercializes Vancocin(R), approved for oral administration for treatment ofantibiotic-associated pseudomembranous colitis caused by Clostridium difficileand enterocolitis caused by Staphylococcus aureus, includingmethicillin-resistant strains (for prescribing information, please downloadthe package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm).ViroPharma currently focuses its drug development activities in viral diseasesincluding cytomegalovirus (CMV) and hepatitis C (HCV). For more information onViroPharma, visit the company's website at www.viropharma.com.

SOURCE ViroPharma Incorporated


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store

Facebook